1204295-87-3 Usage
General Description
2-Bromo-4-(difluoromethyl)pyridine is a chemical compound with the molecular formula C6H4BrF2N. It is a pyridine derivative that has a bromine atom at the 2-position and a difluoromethyl group at the 4-position of the pyridine ring. 2-Bromo-4-(difluoromethyl)pyridine is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also utilized as an intermediate in the production of specialty chemicals and can be used as a reagent in organic synthesis. 2-Bromo-4-(difluoromethyl)pyridine is known for its potential as a bioactive compound and has been the subject of scientific research for its pharmacological properties. However, it is important to handle this compound with caution as it is classified as a hazardous substance due to its toxic and flammable nature.
Check Digit Verification of cas no
The CAS Registry Mumber 1204295-87-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,4,2,9 and 5 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1204295-87:
(9*1)+(8*2)+(7*0)+(6*4)+(5*2)+(4*9)+(3*5)+(2*8)+(1*7)=133
133 % 10 = 3
So 1204295-87-3 is a valid CAS Registry Number.
1204295-87-3Relevant articles and documents
SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
-
Page/Page column 144; 400-401, (2021/11/20)
The present disclosure includes substituted tricyclic amides, or analogues thereof of formula (I) (I), wherein X, Y, ring A, R1, R5, R6 and R7 are as defined herein, and compositions comprising compounds of formula (I) that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
BTK INHIBITORS
-
Paragraph 0880, (2014/08/06)
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
